Trial Profile
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 [abatacept] in Subjects With Active Rheumatoid Arthritis on Background DMARDS Who Have Failed Anti-TNF Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ATTAIN
- Sponsors Bristol-Myers Squibb
- 17 Mar 2020 Results (n=978) of retrospective, observational analysis from seven rheumatoid arthritis clinical studies: H9BMCBCDM, H9BMCBCDO, H9BMCBCDV, IM126004, IM119015, IM101029, M10261 geographical information (from Asia, Latin America, RFEE, USA, and Western Europe) assessing regional differences in adverse event rates and disease activity were published in the Rheumatology
- 11 Jun 2016 Results a post hoc analysis from AIM and ATTAIN and AGREE (n=1536) presented at the 17th Annual Congress of the European League Against Rheumatism
- 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.